Aravive announced the presentation of a poster featuring batiraxcept data in clear cell renal cell carcinoma at the upcoming American Society of Clinical Oncology 2023 Annual Meeting, being held June 2-6, 2023 in Chicago, Illinois and virtually. In addition, an abstract highlighting batiraxcept data in pancreatic adenocarcinoma was accepted for publication.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARAV:
- Aravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual Meeting
- Aravive Appoints Carolina Petrini as Chief Commercial Officer
- Aravive appoints Petrini as Chief Commercial Officer
- Aravive price target raised to $12 from $7 at H.C. Wainwright
- Aravive expects cash to sustain operations into Q4
